BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, September 23, 2023
Home » Topics » Analysis and data insight

Analysis and data insight
Analysis and data insight RSS Feed RSS

Biggest gainers and losers for the week of Aug. 3-7, 2020

Aug. 7, 2020
No Comments
The top 10 biopharma stock gainers and losers for the week.
Read More
Coronavirus cash

Pandemic developers account for 40% of 2020’s record financings

Aug. 7, 2020
By Karen Carey
No Comments
Out of 922 biopharma financings so far in 2020, nearly a quarter of them – 211 – were done by companies working on a COVID-19 therapeutic or vaccine. More strikingly, however, the $27.8 billion raised by those pandemic-focused firms represents about 40% of the $71.8 billion total collected through the end of July. That amount is the highest BioWorld has ever tracked.
Read More
IPO stock market ticker

Appetite for U.S. biopharma IPOs remains hot in July

Aug. 4, 2020
By Peter Winter
No Comments
The biopharmaceutical sector welcomed a further 11 new IPO graduates in July, bringing the number to 39 that have started to trade on the U.S. markets this year. The companies going public last month collectively raised more than $2.5 billion and most of them made a favorable impression following their first day of trading, with the group increasing their share values by an average of 16%.
Read More
Global map, financial charts

Summertime blues for top-tier biopharmaceutical companies

Aug. 3, 2020
By Peter Winter
No Comments
The share prices of blue-chip biopharmaceutical companies continued on their lackluster trajectory, which started in June and collectively lost ground last month, with the BioWorld Biopharmaceutical index slipping about 1.3% as investors took a break in order to digest the deluge of COVID-19 vaccine data released during the period and the impact on the bottom lines that the pandemic has exerted among those companies that have reported their second-quarter results.
Read More

Week in review for July 27-31, 2020: Potential COVID-19 cell therapy treatments in development

Aug. 3, 2020
By Peter Winter
No Comments
A quick look back at top stories.
Read More
Coronavirus and coins

Big biopharma money in July for COVID-19 grants and nonprofit deals

July 31, 2020
By Karen Carey
No Comments
Out of the $10.45 billion brought into the biopharma industry this year by way of collaborations with nonprofit entities or through grants, 80% is focused on COVID-19 therapeutics and vaccines.
Read More

Biopharma money raised: Jan. 1-July 30, 2020

July 31, 2020
No Comments
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More

Money raised by biopharma: 2020 vs. 2019

July 31, 2020
No Comments
Total raised in public, private and other financings of biopharma companies, comparing 2020 vs. 2019.
Read More

Money raised by biopharma: 2020 vs. 2019

July 31, 2020
No Comments
Total raised in public, private and other financings of biopharma companies, comparing 2020 vs. 2019.
Read More

Med-tech gainers and losers for July 27-31, 2020

July 31, 2020
No Comments
The top 10 med-tech stock gainers and losers for the week.
Read More
Previous 1 2 … 122 123 124 125 126 127 128 129 130 … 173 174 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 22, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 22, 2023.
  • Hands holding torn contract

    Quite a fix: Orthofix sacks three top execs

    BioWorld MedTech
    Orthofix Medical Inc. terminated its CEO, chief financial officer and chief legal officer in a move that plunged the stock from $18.63 at Monday’s close to $13.01...
  • Illustration of Alzheimer’s in the brain.

    Study identifies cause of death for Alzheimer’s neurons

    BioWorld
    By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...
  • New NLRP3 inflammasome inhibitors named in PTC Therapeutics patent

    BioWorld Science
    PTC Therapeutics Inc. has patented new NLRP3 inflammasome inhibitors reported to be useful...
BioFuture ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing